Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. [electronic resource]
Producer: 20140826Description: 285-96 p. digitalISSN:- 1872-6054
- Adalimumab
- Anti-Inflammatory Agents -- economics
- Antibodies, Monoclonal, Humanized -- economics
- Antineoplastic Agents -- economics
- Benzamides -- economics
- Decision Making
- Drug Costs -- statistics & numerical data
- Economics, Pharmaceutical
- Evidence-Based Practice
- Filgrastim
- Granulocyte Colony-Stimulating Factor -- economics
- Health Expenditures -- statistics & numerical data
- Humans
- Imatinib Mesylate
- Insurance, Health, Reimbursement -- economics
- Netherlands
- Piperazines -- economics
- Polyethylene Glycols
- Pyrimidines -- economics
- Recombinant Proteins -- economics
- Reimbursement Mechanisms
- Uncertainty
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.